Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration.

ABSTRACT: Over the past decade, there had been progress in the development of cell therapy for insulin-dependent diabetes. Nevertheless, important hurdles that need to be overcome still remain. Protocols for the differentiation of pluripotent stem cells into pancreatic progenitors or fully differentiated β-cells have been developed. The resulting insulin-producing cells can control chemically induced diabetes in rodents and were the subject of several clinical trials. However, these cells are immunogenic and possibly teratogenic for their transplantation, and an immunoisolation device and/or immunosuppression is needed. A growing number of studies have utilized genetic manipulations to produce immune evasive cells. Evidence must be provided that in addition to the expected benefit, gene manipulation

SUBMITTER: Ghoneim MA 

PROVIDER: S-EPMC10823744 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature